Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy

Vaccine

Volumn 22, Issue 27-28, 2004, Pages 3744-3750

  Vindurampulle, Christofer J ^a   Cuberos, Lilian F ^a   Barry, Eileen M ^a   Pasetti, Marcela F ^a   Levine, Myron M ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Infectious diseases; Prime boost strategy; Salmonella enterica serovar Typhi

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; NEUTRALIZING ANTIBODY; TETANUS TOXIN; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; FEMALE; IMMUNOPROPHYLAXIS; INFECTION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SALMONELLA ENTERICA; SALMONELLOSIS; SEROTYPE; STATISTICAL SIGNIFICANCE; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; CELL COUNT; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; SALMONELLA ENTERICA; SALMONELLA VACCINES; SPLEEN; TETANUS TOXIN; TETANUS TOXOID; VACCINES, SYNTHETIC;

EID: 4143082684     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.025     Document Type: Article

References (48)

1. Hone D.M., Harris A.M., Chatfield S., Dougan G., Levine M.M. Construction of genetically defined double aro mutants of Salmonella Typhi. Vaccine. 9(11):1991;810-816
2. Tacket C.O., Hone D.M., Curtiss R. III, Kelly S.M., Losonsky G., Guers L., et al. Comparison of the safety and immunogenicity of ΔaroC ΔaroD and Δcya Δcrp Salmonella Typhi strains in adult volunteers. Infect Immun. 60(2):1992;536-541
3. Tacket C.O., Hone D.M., Losonsky G.A., Guers L., Edelman R., Levine M.M. Clinical acceptability and immunogenicity of CVD 908 Salmonella Typhi vaccine strain. Vaccine. 10(7):1992;443-446
4. Hone D.M., Harris A.M., Levine M.M. Adaptive acid tolerance response by Salmonella Typhi and candidate live oral typhoid vaccine strains. Vaccine. 12(10):1994;895-898
5. Hone D.M., Harris A.M., Lim V., Levine M.M. Construction and characterization of isogenic O-antigen variants of Salmonella Typhi. Mol. Microbiol. 13(3):1994;525-530
6. Sztein M.B., Wasserman S.S., Tacket C.O., Edelman R., Hone D., Lindberg A.A., et al. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella Typhi. J. Infect. Dis. 170(6):1994;1508-1517
7. Cryz S.J. Jr., Que J.U., Levine M.M., Wiedermann G., Kollaritsch H. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella Typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults. Infect Immun. 63(4):1995;1336-1339
8. Giron J.A., Xu J.G., Gonzalez C.R., Hone D., Kaper J.B., Levine M.M. Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by ΔaroC, ΔaroD Salmonella Typhi vaccine strain CVD 908. Vaccine. 13(10):1995;939-946
9. Gomez-Duarte O.G., Galen J., Chatfield S.N., Rappuoli R., Eidels L., Levine M.M. Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella Typhi CVD 908 vaccine strain. Vaccine. 13(16):1995;1596-1602
10. Sztein M.B., Tanner M.K., Polotsky Y., Orenstein J.M., Levine M.M. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella Typhi in humans. J. Immunol. 155(8):1995;3987-3993
11. Barry E.M., Gomez-Duarte O., Chatfield S., Rappuoli R., Pizza M., Losonsky G., et al. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella Typhi vaccine strain CVD 908. Infect Immun. 64(10):1996;4172-4181
12. Levine M.M., Galen J., Barry E., Noriega F., Chatfield S., Sztein M., et al. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors. J. Biotechnol. 44(1-3):1996;193-196
13. Galen J.E., Gomez-Duarte O.G., Losonsky G.A., et al. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella Typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine. 15(6-7):1997;700-708
14. Levine MM, Galen J, Barry E, et al. Attenuated Salmonella Typhi and Shigella as live oral vaccines and as live vectors. Behring Inst. Mitt. 1997;98:120-3.
15. Tacket C.O., Kelly S.M., Schodel F., Losonsky G., Nataro J.P., Edelman R., et al. Safety and Immunogenicity in humans of an attenuated Salmonella Typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun. 65(8):1997;3381-3385
16. Tacket C.O., Sztein M.B., Losonsky G.A., Wasserman S.S., Nataro J.P., Edelman R., et al. Safety of live oral Salmonella Typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun. 65(2):1997;452-456
17. Gonzalez C.R., Noriega F.R., Huerta S., Santiago A., Vega M., Paniagua J., et al. Immunogenicity of a Salmonella Typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine. 16(9-10):1998;1043-1052
18. Galen J.E., Nair J., Wang J.Y., Wasserman S.S., Tanner M.K., Sztein M.B., et al. Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella Typhi CVD 908-htrA. Infect. Immun. 67(12):1999;6424-6433
19. Levine M.M., Ferreccio C., Abrego P., Martin O.S., Ortiz E., Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella Typhi live oral. Vaccine. 17(Suppl 2):1999;S22-S27
20. Orr N., Galen J.E., Levine M.M. Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM(197) and its fragments in Salmonella Typhi vaccine strain CVD 908-htrA. Infect. Immun. 67(8):1999;4290-4294
21. Pasetti M.F., Anderson R.J., Noriega F.R., Levine M.M., Sztein M.B. Attenuated ΔguaBA Salmonella Typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin. Immunol. 92(1):1999;76-89
22. Pasetti M.F., Pickett T.E., Levine M.M., Sztein M.B. A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model. Vaccine. 18(28):2000;3208-3213
23. Pickett T.E., Pasetti M.F., Galen J.E., Sztein M.B., Levine M.M. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect. Immun. 68(1):2000;205-213
24. Tacket C.O., Galen J., Sztein M.B., Losonsky G., Wyant T.L., Nataro J., et al. Safety and immune responses to attenuated Salmonella enterica serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin. Immunol. 97(2):2000;146-153
25. Tacket C.O., Sztein M.B., Wasserman S.S., Losonsky G., Kotloff K.L., Wyant T.L., et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in US volunteers. Infect Immun. 68(3):2000;1196-1201
26. Wang J.Y., Noriega F.R., Galen J.E., Barry E., Levine M.M. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar Typhi oral vaccine strain CVD 909. Infect Immun. 68(8):2000;4647-4652
27. Wu S., Beier M., Sztein M.B., Galen J., Pickett T., Holder A.A., et al. Construction and immunogenicity in mice of attenuated Salmonella Typhi expressing Plasmodium falciparum merozoite surface protein 1 (MSP-1) fused to tetanus toxin fragment C. J. Biotechnol. 83(1-2):2000;125-135
28. Gomez-Duarte O.G., Pasetti M.F., Santiago A., Sztein M.B., Hoffman S.L., Levine M.M. Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains. Infect. Immun. 69(2):2001;1192-1198
29. Levine M.M., Tacket C.O., Sztein M.B. Host-Salmonella interaction: human trials. Microbes Infect. 3(14-15):2001;1271-1279
30. Orr N., Galen J.E., Levine M.M. Novel use of anaerobically induced promoter, dmsA, for controlled expression of fragment C of tetanus toxin in live attenuated Salmonella enterica serovar Typhi strain CVD 908-htrA. Vaccine. 19(13-14):2001;1694-1700
31. Wang J.Y., Pasetti M.F., Noriega F.R., Anderson R.J., Wasserman S.S., Galen J.E., et al. Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated ΔguaBA Salmonella enterica serovar Typhi strain CVD 915. Infect Immun. 69(8):2001;4734-4741
32. Pasetti M.F., Levine M.M., Sztein M.B. Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine. 21(5-6):2003;401-418
33. Salerno-Goncalves R., Wyant T.L., Pasetti M.F., Fernandez-Vina M., Tacket C.O., Levine M.M., et al. Concomitant Induction of CD4(+) and CD8(+) T Cell Responses in Volunteers Immunized with Salmonella enterica Serovar Typhi Strain CVD 908-htrA. J. Immunol. 170(5):2003;2734-2741
34. McShane H., Brookes R., Gilbert S.C., Hill A.V. Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun. 69(2):2002;681-686
35. Londono-Arcila P., Freeman D., Kleanthous H., O'Dowd A.M., Lewis S., Turner A.K., et al. Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect Immun. 70(9):2002;5096-5106
36. Lee C.K., Soike K., Giannasca P., Hill J., Weltzin R., Kleanthous H., et al. Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori. Vaccine. 17(23-24):1999;3072-3082
37. Schneider J., Langermans J.A., Gilbert S.C. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine. 19(32):2001;4595-4602
38. Sabbaj S., Mulligan M.J., Hsieh R.H., Belshe R.B., McGhee J.R. Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group. Aids. 14(10):2000;1365-1374
39. Hoffman S.L., Doolan D.L. Can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunization? Dev. Biol. (Basel). 104:2000;121-132
40. Jespersgaard C., Zhang P., Hajishengallis G., Russell M.W., Michalek S.M. Effect of attenuated Salmonella enterica serovar Typhimurium expressing a Streptococcus mutans antigen on secondary responses to the cloned protein. Infect Immun. 69(11):2001;6604-6611
41. Mollenkopf H.J., Groine-Triebkorn D., Andersen P., Hess J., Kaufmann S.H. Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella Typhimurium vaccine carrier strain and expressed by naked DNA. Vaccine. 19(28-29):2001;4028-4035
42. Evans D.T., Chen L.M., Gillis J., Lin K.C., Harty B., Mazzara G.P., et al. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J. Virol. 77(4):2003;2400-2409
43. Lasaro M.O., Alves A.M., Guillobel H.C., Almelda D.F., Ferreira L.C., Anderson R., et al. New vaccine strategies against enterotoxigenic Escherichia coli. II. Enhanced systemic and secreted antibody responses against the CFA/I fimbriae by priming with DNA and boosting with a live recombinant Salmonella vaccine strain: expression levels and immune response. Braz. J. Med. Biol. Res. 32(2):1999;241-246
44. Anderson R., Dougan G., Roberts M. Delivery of the Pertactin/P.69 polypeptide of Bordetella pertussis using an attenuated Salmonella Typhimurium vaccine strain: expression levels and immune response. Vaccine. 14(14):1996;1384-1390
45. Xu F., Hong M., Ulmer J.B. Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella. Vaccine. 21(7-8):2003;644-648
46. Devico A.L., Fouts T.R., Shata M.T., Kamin-Lewis R., Lewis G.K., Hone D.M. Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine. 20(15):2002;1968-1974
47. Helting T.B., Nau H.H. Analysis of the immune response to papain digestion products of tetanus toxin. Acta Pathol. Microbiol. Immunol. Scand. [C]. 92(1):1984;59-63
48. Coffman R.L., Seymour B.W., Lebman D.A., Hiraki D.D., Christiansen J.A., Shrader B., et al. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev. 102:1988;5-28